Geron appoints John F. McDonald to Board of Directors

GERON CORP

John F. McDonald appointed as Class I director, term expiring at 2024 annual meeting.
McDonald is Corporate VP, Global R&D Business Development at Novo Nordisk; previously VP at Biogen.
Received initial option grant for 200,000 shares at $2.72/share, vesting over 3 years.
Eligible for annual option grants of 125,000 shares and $42,500 cash retainer.
Board determined McDonald is independent under Nasdaq and SEC rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John F. McDonald

Director

GERN · GERON CORP

Effective: 2022-09-07
Filed: September 8, 2022, 7:59 PM ET

appointed John F. McDonald to the Board, effective immediately, as a Class I Board member

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John F. McDonald was appointed as Director at GERON CORP.

Action: appointed
Role: Director

Exact text from the filing

appointed John F. McDonald to the Board, effective immediately, as a Class I Board member

View on SEC.gov

GERON CORP filing history →

Source: SEC EDGAR

accession 0000950170-22-018252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.